Spherix Announces Settlement Agreement and Continued Monetization of Patent Portfolio

Spherix Incorporated (SPEX) -- an intellectual property development company committed to the fostering and monetization of intellectual property, announced today that its wholly owned subsidiary, CompuFill LLC, has entered into a settlement and license agreement with a leading technology company.

This is the first settlement and license agreement for the CompuFill portfolio since Spherix acquired North South Holdings Inc. in September of 2013. Ongoing infringement enforcement continues as Spherix's model of patent monetization grows in both scope and size.

The CompuFill patents, each in the "on-line pharmacy automated refill system" sector, trace priority back to October 1997.

Read more: Spherix Incorporated ( SPEX )

Cadence Pharmaceuticals Reports Positive Outcome In OFIRMEV® Patent Litigation

Cadence Pharmaceuticals, Inc. (CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the U.S. District Court for the District of Delaware has ruled in favor of Cadence in the company's patent infringement lawsuit against Exela Pharma Sciences, LLC. 

"We are very pleased with the Court's decision, as it confirms our belief in the strength and validity of the patents covering OFIRMEV," said Ted Schroeder, president and chief executive officer of Cadence. "Our focus remains on continuing to drive OFIRMEV's strong performance. We continue to gain market share and posted year-over-year sales growth of more than 100% in each quarter of 2013. We remain confident in our franchise, and look forward to updating investors further on our progress."

Read more: Cadence Pharmaceuticals Inc ( CADX )

Vanda Pharmaceuticals Reports Third Quarter 2013 Results

Vanda Pharmaceuticals Inc. (Vanda) (VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2013.

Key Highlights:

Shire to Acquire ViroPharma in Strategic Move to Strengthen Rare Disease Portfolio; Will Augment Already Strong Growth Prospects

Earnings accretive, revenue growth-enhancing acquisition

Shire plc (LSE: SHP, NASDAQ: SHPG) and ViroPharma Incorporated (VPHM) today announce that their Boards of Directors have unanimously approved, and the companies have entered into, a merger agreement pursuant to which Shire will acquire all the outstanding shares of the rare disease company ViroPharma for $50 per share in cash, for a total consideration of approximately $4.2 billion.  The $50 per share price in the transaction represents a 27% premium to ViroPharma's closing share price on Friday, November 8, 2013, the last trading day prior to announcement, and a 64% premium to ViroPharma's unaffected share price of $30.47 on September 12, 2013.

Read more: ViroPharma Incorporated ( VPHM )

NW Bio's DCVax Featured On Fox News And Fox Business News

NYU's Dr. Marc Siegel Discusses DCVax And Its Life-Extending Potential As A Cancer Therapy

Northwest Biotherapeutics (NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that their vaccine was featured yesterday in news coverage on both Fox News and Fox Business News.

The segment was hosted for Fox by Dr. Marc Siegel, a Clinical Associate Professor at NYU's Langone Medical Center, who describes Northwest Biotherapeutics's DCVax as a potential life-extending treatment for all solid tumor cancers by using biomarkers from the patient's own tumor cells to activate the patient's immune system to fight the cancer in the patient's body.

Read more: Northwest Biotherapeutics ( NWBO )
Copyright © 2025 Stock Junction. All Rights Reserved.